Convenience of Hgb-O detected by optical method in XN-series hematology analyzers in evaluating hemoglobin concentration in samples with chylous turbidity

Yu Aruga, Chiaki Ikeda, Arisa Hanai, Sakiko Yoshimura, Momoko Kito, Satoe Miyaki, Misato Tsukokura, Yuka Yasuno, Chiaki Hayashi, Motoi Miyakoshi, Takahiro Nishino, Kimihiko Kawamura & Hiromichi Matsushita

The chylous turbidity of blood samples is one of the causes of false-high hemoglobin (Hgb) concentration measurements by the colorimetric method, which has been widely applied in hematology analyzers. In such cases, additional manual procedures are required to correct Hgb concentrations. We therefore examined the effectiveness of an optical method for measuring Hgb concentrations in samples with chylous turbidity using Hgb-O in the reticulocyte channel equipped in XN-series analyzers (Sysmex, Kobe, Japan). Hgb-O showed excellent basic performance, including linear correlation and invariability with sodium lauryl sulfate (SLS)-Hgb detected by the colorimetric method. In the analysis of samples from healthy volunteers supplemented with fat emulsion, chylous turbidity did not affect Hgb-O but SLS-Hgb, which was falsely increased according to the dose of fat emulsion. Actually, SLS-Hgb was falsely elevated in 34 of 40 chylous turbidity 3+ samples. The remaining 6 samples were measured in hematology analyzers where Hgb-O was inconsistent with SLS-Hgb in the internal quality control records. For these samples, the correction factors calculated from the internal quality control records could contribute to providing the corrected Hgb-O value. These findings suggested that the optical method was effective and convenient for accurately evaluating Hgb concentrations in samples with extremely chylous turbidity.

The hemoglobin (Hgb) concentration, one of the most important components of complete blood count (CBC), is utilized for evaluating the anemic and polycythemic status of patients. The colorimetric method using hemolysis enables large numbers of samples to be processed in a short time; thus, this method has been widely used in the measurement of Hgb concentrations by hematology analyzers. However, co-existing substances are assumed to cause false-high Hgb concentrations because they affect the color of sample solutions after hemolysis.

Chyle, a milky fluid in the blood, is capable of causing analytical interference in biochemical examinations using colorimetric methods, the quantification of serum proteins using immunoturbidimetric assays, and coagulation tests through lipid particles, in addition to falsely decreased electrolyte concentrations due to its volume displacement effect. It is also known to be one of the major substances to cause false-high Hgb concentrations. It is generated by metabolic abnormalities, including dyslipidemia, hyperlipidemia after meals, and the intravenous administration of fatty emulsion. The degree of chylous turbidity varies, and the correction of measured Hgb concentrations is needed if a blood sample has extremely chylous turbidity. The correction is generally made through the retraction of the supernatant Hgb concentration from the Hgb concentration of whole blood after hemolysis or the measurement of the Hgb concentration after the replacement of chylous plasma by isotonic saline. However, these conventional correction methods require additional manual procedures, such as centrifugal separation, fractionation of supernatant, and replacement of chylous plasma by buffer solution, which may negatively affect the accuracy of laboratory testing.
Many hematology analyzers are equipped with a basic automated operation to evaluate the Hgb concentration using an optical method through the flow cytometric function. Because the optical method requires neither hemolysis nor additional procedures, it may be possible to determine the Hgb concentration with high accuracy in a short time, in case the Hgb concentration measured using the colorimetric method is not secured due to interference by co-existing substances, such as chyle.

The aim of the present study was to validate the effectiveness and convenience of the optical method in the measurement of Hgb concentrations in samples with chylous turbidity.

Results
Basic performance of Hgb-O. XN-10 and XN-20 (Sysmex, Kobe, Japan) hematology analyzers were utilized in this study. These devices apply the colorimetric Hgb method using a non-cyanic substrate, sodium lauryl sulfate (SLS-Hgb), as a regular method to qualify the Hgb concentration as well, as an optical method of measuring Hgb (Hgb-O) in the reticuloocyte (RET) channel, which has not yet been validated in clinical use.

The principle of Hgb-O is as follows: in the RET channel, the CELLPACK DFL™ reagent (Sysmex) generates pores on the cellular membrane of erythrocytes, and the Fluorocell™ RET reagent (Sysmex) stains the inside of erythrocytes. RBC-Y, which is defined as the most frequent value of forward scatter in mature erythrocyte population, is converted to RBC Hgb equivalent (RBC-He), which shows a high correlation with the mean corpuscular hemoglobin (MCH) value. Hgb-O is calculated assuming RBC-He as MCH.

First, the basic performance of Hgb-O was analyzed to validate Hgb-O as a clinical laboratory test. The correlation with SLS-Hgb in each analyzer (No.1 to No.4, XN-10; No. 5, XN-20) was evaluated using the recorded data from the same patients (n = 1140). The regression equation and correlation coefficient were calculated (Supplementary Table S1). The slopes of these equations were 0.998 to 1.070 and all of their correlation coefficients were > 0.980.

The repeatability was evaluated using the coefficient of variation (CV) in 10 consecutive measurements of Hgb-O and SLS-Hgb, which were 0.7 to 1.8% and 0.3 to 0.7%, respectively. Hgb-O showed a larger CV than SLS-Hgb; however, the CV for Hgb-O was still < 2.0% (Supplementary Table S2).

The interference of co-existing substances with the Hgb measurement was evaluated using Interference check A plus (Sysmex). In comparison to SLS-Hgb, the variations (the differences between the maximal and minimal values) of the Hgb-O measurement was smaller in the presence of cell-free Hgb (up to 0.48 g/dL) or chyle (up to 590 FTU), and larger in the presence of indirect or conjugated bilirubin (up to 18.8 mg/dL and 20.2 mg/dL, respectively). In all cases, the variation in the Hgb-O measurement was < 0.3 g/dL (Supplementary Table S2).

These findings demonstrated that Hgb-O had excellent correlation and consistency with SLS-Hgb and that the CVs for the repeatability and variations under the effects of coexisting substrate on Hgb-O measurement were small enough to be negligible. However, the concentrations of triglyceride (TG) and total cholesterol (T-Chol) increased by 3% in samples with chylous turbidity due to the addition of maximal dose (590 FTU) of chyle included in Interference check A plus were 76 mg/dL and 3 mg/dL, respectively, which were much lower in comparison to T-Chol levels in clinical practice.

Evaluation of the suitability of Hgb-O for the analysis of samples with chylous turbidity. In order to evaluate the interference of chylous turbidity in the measurement of Hgb in medical practice, samples supplemented with intravenous fat emulsion, which mainly included TG, were prepared to measure Hgb-O and SLS-Hgb. Increasing the fat emulsion to 1.0% (v/v) in the samples caused the serum appearance to change to a strawberry milk color due to the marked increase in the TG concentration and the resultant hemolysis in the 3 blood samples; the concentrations of serum TG ranged from 42, 114 and 55 mg/dL without fat emulsion to 1694, 1764 and 1885 mg/dL with 1.0% (v/v) fat emulsion, in a dose-dependent manner (Fig. 1a). In contrast, the T-Chol concentration was less markedly affected than the TG concentration in these samples; the T-Chol concentrations ranged from 143 to 162 mg/dL, 170 to 190 mg/dL, and 207 to 198 mg/dL in the 3 blood samples. As expected, the SLS-Hgb level in these samples increased from 13.5 to 15.9 g/dL, 12.1 to 14.5 g/dL, and 14.9 to 17.4 g/dL (Fig. 1b), and the MCHC that was calculated using SLS-Hgb increased accordingly from 35.1 to 41.4 g/dL, 34.0 to 41.1 g/dL, and 34.8 to 39.7 g/dL in each sample (Fig. 1c). The Hgb-O concentration was slightly increased from 10.1 to 11.6 g/dL, 9.7 to 11.4 g/dL, and 11.3 to 12.6 g/dL in the chylous turbidity 1+, 2+ and 3+ samples, respectively. In all cases, the variation in the Hgb-O measurement was < 0.3 g/dL (Supplementary Table S2). The ΔHgb value ranged from 0.0 to 0.2 g/dL (median 0.1 g/dL). However, the concentrations of triglyceride (TG) and total cholesterol (T-Chol) were still close to those of corrected Hgb (see Materials and methods 3. Calculation of corrected Hgb for SLS-Hgb), suggesting, in contrast to SLS-Hgb, that Hgb-O did not show a false-high value due to the addition of fat emulsion (Fig. 1b).

We then investigated the effect of coexisting chylous turbidity on Hgb measurement using data from patient samples to validate the above-described results. The frequency of chylous turbidity negativity, 1+, 2+ and 3+ in each sample was 87.4%, 11.6%, 0.9% and 0.1%, respectively. TG increased according to the elevation of chylous turbidity; the median TG values in chylous turbidity negative, 1+, 2+ and 3+ peripheral blood samples were 109 mg/dL, 184 mg/dL, 382 mg/dL and 736 mg/dL, respectively. T-Chol also increased but mildly; the medians of T-Chol in the peripheral blood with chylous turbidity negative, 1+, 2+ and 3+ were 194 mg/dL, 214 mg/dL, 307 mg/dL and 233 mg/dL, respectively (Fig. 2a). Spearman’s rank correlation coefficient (ρ) was 0.75 (95% CI: 0.69–0.79) between chylous turbidity and TG whereas it was 0.23 (95% CI: 0.11–0.33) between chylous turbidity and T-Chol, suggesting that chylous turbidity was more strongly correlated with TG than T-Chol, as seen in the recorded data from the same patients (n = 1140). The regression equation and correlation coefficient were calculated (Supplementary Table S1).
turbidity 3+ samples showed a high frequency of hemolysis (2+, n = 5, 12.5%; 1+, n = 10, 25.0%; +/−, n = 22, 55.0%) (Supplementary Table S3), indicating a sharp contrast to the frequency of hemolysis samples: 3+, 0.0%; 2+, 0.1%; 1+, 0.2%; +/−, 1.6%; negativity, 98.1%. On the other hand, Hgb-O was close to the corrected Hgb value and was lower than SLS-Hgb in 34 of the 40 chylous turbidity 3+ samples (Fig. 2b, Supplementary Table S3). Additionally, MCHC was higher than 36.5 g/dL, which was defined as the lower limit of high MCHC values in a previous study9, in 15 of the 40 chylous turbidity 3+ samples, and 10 of these 15 samples showed ΔHgb values of ≥ 1.0 g/dL (Fig. 2c). In all 10 samples, Hgb-O was equal to the corrected Hgb value and was apparently lower than SLS-Hgb (Fig. 2d), which were supported by the 3 mean differences in Hgb values (Δvalues), including ΔHgb, Hgb-O minus corrected Hgb, and SLS-Hgb minus Hgb-O (Fig. 2e). In contrast, there were no samples in which the ΔHgb was ≥ 1.0 g/dL when MCHC was ≤ 36.5 g/dL.

These experimental and clinical observation clearly revealed that TG was the main component of chyle that affected SLS-Hgb but not Hgb-O. It is therefore recommended that Hgb-O be utilized for the measurement of Hgb when a sample is chylous turbidity 3+ with an MCHC value of > 36.5 g/dL.

Investigation of the quality of Hgb-O in hematology analyzers. As shown in Fig. 2b, Hgb-O was equal to or higher than SLS-Hgb in 6 of the 40 chylous turbidity 3+ samples. These results were inconsistent with the experimental data shown in Fig. 1b. The fact that an internal quality control system for Hgb-O has not been established may be one of the reasons for the inconsistency.

In order to investigate the quality status of Hgb-O, the internal quality control records of SLS-Hgb and the corresponding Hgb-O data in each hematology analyzer were compared. First, the regression equations comparing the data from No. 2 to 5 with the reference data from No.1 were calculated. The slopes of the regression equations of SLS-Hgb converged on 0.99 to 1.01, but those of Hgb-O ranged from 0.97 to 1.09. Then, we investigated the time-dependent changes in Hgb-O in comparison to quality-controlled SLS-Hgb using XN-CHECK control blood (Sysmex, Kobe, Japan) in each hematology analyzer between June 2019 and July 2020. There were discrepancies between Hgb-O and SLS-Hgb, and they varied according to the hematology analyzers that were used. The No. 5 hematology analyzer showed good correlation between Hgb-O and SLS-Hgb during the study period (Fig. 3a), and the slope of the regression equation using 100 patient samples was 1.030 (Supplementary

Figure 1. False-high SLS-Hgb values detected in blood samples supplemented with fat emulsion. The blood samples from 3 healthy donors were supplemented with up to 1.0% (w/v) fat emulsion (Intralipos®). Fat emulsion-dependent changes of (a) the serum concentrations of triglyceride, (b) SLS-Hgb, Hgb-O and corrected Hgb, and (c) MCHC are shown. Corr., Corrected.
In 3 chylous turbidity 3+ samples that were measured by the No. 5 hematology analyzer in the study period, Hgb-O was almost equal to the corrected Hgb value, and was always lower than SLS-Hgb (Fig. 3b, c). On the other hand, the No. 3 hematology analyzer showed the constant elevation of Hgb-O in the XN-CHECK Level 1 and 2 measurements (Fig. 3d), therefore the resulting elevation of the slope of the regression equation was 1.098 (Supplementary Fig. S2). Hgb-O measured by the No. 3 hematology analyzer in that period were equal (n = 2) or higher (n = 4) in comparison to SLS-Hgb in 6 chylous turbidity 3+ samples (Fig. 3e). This was consistent with the positive value of the mean difference in Hgb-O minus corrected Hgb and the negative value of the mean difference in SLS-Hgb minus Hgb-O (Fig. 3f).

These findings demonstrate that Hgb-O showed variable discrepancy from SLS-Hgb because the quality of Hgb-O was not controlled. It is therefore important to check the internal quality control records of SLS-Hgb data and the corresponding Hgb-O data before evaluating Hgb-O, in order to see the degree of discrepancy between them.

**Correction of Hgb-O using the internal quality control records.** To overcome discrepancy between the methods, the validity of the correction factors for Hgb-O were verified. The correction factor represented the proportion of the mean SLS-Hgb value to the mean Hgb-O value, which was calculated from the daily quality control data using 5 patient samples in each hematology analyzer. The measured Hgb-O values were multiplied...
by the corresponding correction factor to obtain the corrected Hgb-O value. The discrepancy between SLS-Hgb and Hgb-O in the dairy internal quality control became inconspicuous when Hgb-O was substituted for corrected Hgb-O (Fig. 4a, b). Additionally, all of the corrected Hgb-O calculated from the 6 measured Hgb-O values that were equal to or higher than SLS-Hgb (Figs. 2b, 3f) were almost equal to corrected Hgb, and were equal to \((n = 1)\) or lower than SLS-Hgb (Fig. 4c). In these 6 samples, the mean difference in corrected Hgb-O minus corrected Hgb was almost 0, and the mean difference in SLS-Hgb minus corrected Hgb-O was positive (Fig. 4d).

These findings suggested that the calculation of corrected Hgb-O using the correction factors is reasonable for the evaluation of the Hgb concentration in cases where there is a discrepancy between SLS-Hgb and Hgb-O.

**Discussion**

The current study demonstrates the effectiveness of Hgb-O measured in the RET channel of the XN-10 and XN-20 hematology analyzers using samples with chylous turbidity; Hgb-O not only had good correlation with SLS-Hgb, but also exhibited values that were close to the corrected Hgb value even in the measurement of samples with chylous turbidity where the TG concentration were mainly elevated. An MCHC value of $>36.5$ g/dL was a good parameter to select samples with chylous turbidity $3+$ for the application of Hgb-O. Among these samples, the frequency of samples showing $\geq 1.0$ g/dL of difference between SLS-Hgb and Hgb-O was high. However, there were samples where Hgb-O data required adjustment (shown as corrected Hgb-O), because of the lack of a quality control system.
The colorimetric method detects both cellular and cell-free Hgb without distinguishing between them. Substances, such as cell-free Hgb, bilirubin and chyle, may interfere with measurements and cause false-high Hgb values when using the colorimetric method\(^1\). In particular, severe chylous turbidity with a high TG concentration has been reported to induce hemolysis\(^15,16\), which was also seen in the artificially generated samples supplemented with intravenous fat emulsion (Fig. 1b) and in the clinical samples (Supplementary Table S3), exacerbating the false-high SLS-Hgb value caused by chyle. It is obvious that the most beneficial advantage of optical methods, such as Hgb-O, is that they are able to selectively detect cellular hemoglobin. Notably, the present study revealed that Hgb-O was scarcely affected by 18.8 mg/dL of indirect bilirubin and 20.2 mg/dL of conjugated bilirubin in the present study, although SLS-Hgb also showed an insusceptibility to co-existing bilirubin (Supplementary Table S2). Therefore, Hgb-O measurement is effective for samples with severe chylous turbidity, which interrupted the SLS-Hgb measurement due to a false-high value.

Although hematology analyzers from various manufactures are often equipped with a system for detecting cellular hemoglobin, a limited number of reports related to the optical method of Hgb measurement have been published. Kunicka et al. reported that the optical method showed good correlation with the colorimetric method when using the ADVIA 120 system (Siemens)\(^17\). Berda-Haddad et al. suggested that Hgb-O was one of the recommended tools for the evaluation of the Hgb concentration in samples with MCHC values of > 36.5 g/dL\(^9\). Gönel et al. reported that cellular Hgb measured by the optical method using the CELLDYN Ruby System (Abbott, Lake Forest, USA) was effective for obtaining the correct Hgb value in an excessively lipemic sample\(^18\). However, the former study did not show the effectiveness of the colorimetric method for the analysis of chylous samples, and the latter two only included a small number of chylous samples. Thus, the current study is the first report to clearly describe the convenience of the optical method for the measurement of Hgb in chylous samples with detailed analyses for practical use.

MCHC, an important parameter for chylous samples, is also elevated under several conditions, including hyposmolar plasma conditions and under conditions of erythrocyte diseases, such as intravascular hemolysis, erythrocyte agglutination, hereditary spherocytosis and sickle cell anemia. The upper limit of the reference range of MCHC is generally defined as 36.0 g/dL, and MCHC values of > 36.0 g/dL are rarely observed\(^19-21\). Actually,

---

**Figure 4.** The correction of Hgb-O by the correction factor. (a) The time-dependent changes of quality-controlled SLS-Hgb, Hgb-O and corrected Hgb-O in the No. 3 hematology analyzer. The corrected Hgb-O was calculated using the correction factor for Hgb-O, which is shown in (b). (c) The comparison of SLS-Hgb, corrected Hgb and corrected Hgb-O, instead of Hgb-O, of the 6 samples (D to I) as shown in Fig. 3d. (d) The differences in Hgb values (Δvalues) including corrected Hgb-O minus corrected Hgb and SLS-Hgb minus corrected Hgb-O. The mean values with 95% CI are shown. Corr., Corrected.
defined chylous index 1, 2 to 3, and ≥ 4 as chylous turbidity 1+, 2+, and 3+, respectively. This was calculated by dividing the absorbance at a wavelength of 660 to 700 nm by 320. Our institute in Japan). The analyzer could provide the chylous index, which expressed cloudiness due to chyle, to evaluate samples.

**Materials and methods**

**Evaluation of the basic performance of Hgb-O.** The correlation between Hgb-O and SLS-Hgb, including the regression equation and correlation coefficient was evaluated using the hematological data of patient samples recorded in the XN-10 and XN-20 hematology analyzers between June 2019 to June 2020 (n = 1140) for internal quality control.

Repeatability was evaluated by the coefficient of variation (CV), which was calculated by 10-times measurement in 3 patient samples with different Hgb concentrations (low, 1; intermediate, 1; high, 1).

The interference of coexisting substances was evaluated based on the changes in the mean values of triplicate measurements after the addition of various concentrations of substances (cell-free Hgb, indirect or conjugated bilirubin, and chyle) included in the Interference check A plus (Sysmex).

**Interference of chylous turbidity in Hgb measurement using artificially generated samples.** Nine volumes of blood samples obtained from 3 healthy volunteers were mixed with one volume of saline, which was serially-diluted with intravenous fat emulsion Intralipos® Injection10% (Otsuka Pharmaceutical, Tokyo, Japan) to generate blood samples including fat emulsion at a final concentration of 0 to 1.0% (w/v). SLS-Hgb and Hgb-O were measured in triplicate, and the mean values were calculated.

**Calculation of corrected Hgb for SLS-Hgb.** The corrected Hgb value was calculated using the following formula: Corrected Hgb = SLS-Hgb(g/dL) — (1-Hematocrit) × cell-free Hgb (g/dL). The cell-free Hgb was the Hgb concentration in the plasma supernatant which was measured using an XN-10 or XN-20 hematology analyzers after centrifugation (3000 rpm for 5 min).

**Biochemical analyzer and chylous index.** Biochemical analyses, such as the measurement of TG and T-Cho in the serum and plasma, were performed using a LABOSPECT 008 (Hitachi High-Technologies, Tokyo, Japan). The analyzer could provide the chylous index, which expressed cloudiness due to chyle, to evaluate sample quality. This was calculated by dividing the absorbance at a wavelength of 660 to 700 nm by 320. Our institute defined chylous index 1, 2 to 3, and ≥ 4 as chylous turbidity 1+, 2+, and 3+, respectively.

**Investigation of the interference by chylous turbidity in Hgb measurements and the frequency of hemolysis using clinical records.** The frequency of chylous and hemolytic samples, the relationship between chylous index and blood lipid concentrations (TG and T-Cho), the comparison of Hgb-O, SLS-Hgb and corrected Hgb in the 40 chylous 3+ samples, the frequency of high MCHC values measured in our clinical laboratory were evaluated using clinical records from April 2019 to March 2020, April 2019 to March 2020, May 2018 to August 2020, April 2014 to June 2019, respectively.

**Investigation of the quality of Hgb-O in hematology analyzers.** The internal quality control records of SLS-Hgb, as measured using an XN-CHECK control blood (Sysmex) and patient samples from April 2019 to July 2020, and the quality records of Hgb-O in the corresponding period were investigated and compared.

**Statistical analysis.** All statistical analyses were performed using R version 4.0.3. A linear regression analysis and Pearson's correlation coefficient (r) were used for comparison between two measurements or hematology analyzers. Spearman's rank correlation coefficients (ρ) were calculated to evaluate the correlation between chy-
lous turbidity and triglyceride or total cholesterol. The mean values of differences (Δvalue) between two different Hgb measurement methods, including SLS-Hgb, Hgb-O, corrected Hgb and corrected Hgb-O, were calculated with the 95% confidence interval (95% CI).

**Ethical approval.** This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Institutional Review Board of the National Cancer Center (#2016-403 and #2020-125). Written informed consent was obtained from the healthy donors and the patients.

Received: 16 February 2021; Accepted: 5 July 2021
Published online: 22 July 2021

**References**
1. Tracy, I. G. Automated hematology instrumentation. In UpToDate, Post TW (Ed), UpToDate, Waltham, MA.
2. Ralph, G. & Wachsmann-Hogiu, S. Development, history, and future of automated cell counters. *Clin. Lab. Med.* 35, 1–10 (2015).
3. Zandecki, M., Genevieve, F., Gerard, J. & Godon, A. Spurious counts and spurious results on haematology analysers: A review. Part II: White blood cells, red blood cells, haemoglobin, red cell indices and reticulocytes. *Int. J. Lab. Hem.* 29, 21–41 (2007).
4. Guder, W. G. et al. The haemolytic, icteric and lipemic sample recommendations regarding their recognition and prevention of clinically relevant interferences. *J. Lab. Med.* 24, 357–364 (2000).
5. Nikolac, N. Lipemia: Causes, interference mechanisms, detection and management. *Biochem. Med.* 24, 57–67 (2014).
6. Bornhorst, J. A., Roberts, R. F. & Roberts, W. L. Assay-specific differences in lipemic interference in native and intralipid-supplemented samples. *Clin. Chem.* 50, 2197–2201 (2004).
7. Lippi, G., Plebani, M. & Favaloro, E. J. Interference in coagulation testing: Focus on spurious hemolysis, icterus, and lipemia. *Semin. Thromb. Hemost.* 39, 258–266 (2013).
8. Zeng, S. G. et al. A simple, fast correction method of triglyceride interference in blood hemoglobin automated measurement. *J. Clin. Lab. Anal.* 27, 341–345 (2013).
9. Berda-Haddad, Y. et al. Increased mean corpuscular haemoglobin concentration: Artefact or pathological condition?. *Int. J. Lab. Hem.* 39, 32–41 (2017).
10. Cornbleet, J. Spurious results from automated hematology cell counters. *Lab. Med.* 14, 509–514 (1983).
11. Krasowski, M. D., Kelly, K. Hematology in the physician office laboratory. Module #12 of the CLIA Lab Director Certification Course. https://webapps1.healthcare.uiowa.edu/OnlineEducation/Documents/HematologySection.pdf. Accessed 13 July 2021.
12. Oshiro, I., Takenaka, T. & Maeda, J. New method for hemoglobin determination by using sodium lauryl sulfate (SLS). *Clin. Biochem.* 15, 83–88 (1982).
13. Karsan, A., MacLaren, I., Conn, D. & Wadsworth, L. An evaluation of hemoglobin determination using sodium lauryl sulfate. *Am. J. Clin. Pathol.* 100, 123–126 (1993).
14. Franck, S., Linssen, J., Messinger, M. & Thomas, L. Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis. *Clin. Chem.* 50, 1240–1242 (2004).
15. Dimeski, G., Mollee, P. & Carter, A. Increased lipid concentration is associated with increased hemolysis. *Clin. Chem.* 51, 2425–2430 (2005).
16. Li, G. et al. In vitro and in vivo evaluation of a simple microemulsion formulation for propofol. *Int. J. Pharm.* 425, 53–61 (2012).
17. Kunicka, J. et al. Automated quantitation of hemoglobin-based blood substitutes in whole blood samples. *Am. J. Clin. Pathol.* 116, 913–919 (2001).
18. Gönel, A. & Koyuncu, I. Measurement of the cellular hemoglobin concentration by laser scatter method from excessive lipemic sample: Case report. *Comb. Chem. High Throughput Screen.* 22, 502–505 (2019).
19. Laboratory test normal reference ranges in adults. In: *UpToDate*, Post TW (Ed), UpToDate, Waltham, MA. Accessed 13 July 2021.
20. Sarma, P. R. Chapter 152. Red cell indices. In: *Clinical Methods. The History, Physical, and Laboratory Examinations* 3rd edn (eds Walker, H. K., et al) 720–723 (Butterworths, 1990). https://www.ncbi.nlm.nih.gov/books/NBK266/. Accessed 13 July 2021.
21. Buttarello, M. Laboratory diagnosis of anemia: Are the old and new red cell parameters useful in classification and treatment, how? *Int. J. Lab. Hematol.* 38(Suppl. 1), 123–132 (2016).

**Acknowledgements**
The authors thank all of the members of the Department of Laboratory Medicine for their fruitful discussions.

**Author contributions**
Y.A. and C.I. designed the study, performed the laboratory analyses, performed the data analysis and wrote the manuscript. A.H. performed the laboratory analyses and interpreted data. S.Y., M.K., S.M., M.T. and Y.Y. performed the laboratory analyses. MM and CH interpreted data. T.N. performed the statistical analysis. K.K. interpreted data and provided administrative support for the study, H.M. designed the study, interpreted data, wrote the manuscript and provided administrative support for the study.

**Competing interests**
The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-94394-z.

**Correspondence** and requests for materials should be addressed to H.M.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
